MX2020000376A - Formulaciones farmaceuticas hipercomprimidas. - Google Patents

Formulaciones farmaceuticas hipercomprimidas.

Info

Publication number
MX2020000376A
MX2020000376A MX2020000376A MX2020000376A MX2020000376A MX 2020000376 A MX2020000376 A MX 2020000376A MX 2020000376 A MX2020000376 A MX 2020000376A MX 2020000376 A MX2020000376 A MX 2020000376A MX 2020000376 A MX2020000376 A MX 2020000376A
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulations
lactide
glycolide
hypercompressed
hypercompressed pharmaceutical
Prior art date
Application number
MX2020000376A
Other languages
English (en)
Inventor
Barry M Libin
Jeffrey M Liebmann
Weiliam Chen
Original Assignee
Sustained Nano Systems Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sustained Nano Systems Llc filed Critical Sustained Nano Systems Llc
Publication of MX2020000376A publication Critical patent/MX2020000376A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Una forma de dosis farmacéutica que comprende un polímero de láctido, glicólido o láctido-glicólido, un polímero de bloque de poliglocólido, carbonato de trimetileno, poli-caprolactona, y óxido de polietileno que se combina con un péptido o agente terapéutico de proteína en la forma de micropartículas que se comprimen usando una presión de 3447.37 a 24131.65 Bar.
MX2020000376A 2017-07-11 2018-07-10 Formulaciones farmaceuticas hipercomprimidas. MX2020000376A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762531264P 2017-07-11 2017-07-11
PCT/US2018/041530 WO2019014280A1 (en) 2017-07-11 2018-07-10 HYDRO-PRESSED PHARMACEUTICAL FORMULATIONS

Publications (1)

Publication Number Publication Date
MX2020000376A true MX2020000376A (es) 2020-07-14

Family

ID=65000811

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020000376A MX2020000376A (es) 2017-07-11 2018-07-10 Formulaciones farmaceuticas hipercomprimidas.

Country Status (9)

Country Link
US (1) US10406102B2 (es)
EP (1) EP3651800B1 (es)
CN (1) CN110913907A (es)
AU (1) AU2018300080A1 (es)
BR (1) BR112020000506A2 (es)
CA (1) CA3069159A1 (es)
IL (1) IL271908B2 (es)
MX (1) MX2020000376A (es)
WO (1) WO2019014280A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020000504A2 (pt) * 2017-07-11 2020-07-14 Sustained Nano Systems Llc esterilização por radiação de formas de dosagem de polímeros hipercomprimidos

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5899411A (ja) 1981-12-05 1983-06-13 Shoichiro Ozaki 制ガン剤
CH679207A5 (es) 1989-07-28 1992-01-15 Debiopharm Sa
US6855331B2 (en) 1994-05-16 2005-02-15 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
FR2756493B1 (fr) 1996-12-02 2001-04-13 Delab Dispositif d'administration locale de formulations solides ou semi-solides
DE19856432A1 (de) 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
CA2420621C (en) * 2000-09-28 2011-05-24 Chiron Corporation Microparticle compositions and methods for the manufacture thereof
US20040185095A1 (en) 2002-05-31 2004-09-23 Hanshermann Franke Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release
JP4475891B2 (ja) 2003-06-20 2010-06-09 ホソカワミクロン株式会社 経肺製剤の製造方法
KR101231856B1 (ko) 2004-08-12 2013-02-08 큐피에스 엘엘씨 생물학적 활성 화합물의 제어 방출 전달용 약학 조성물
FR2880273B1 (fr) 2004-12-30 2007-03-30 Ceva Sante Animale Sa Procede de separation d'une composition pharmaceutique solide a liberation prolongee et controlee sous hautes pressions
US20090148498A1 (en) * 2007-05-14 2009-06-11 Sustained Nano Systems Llc Controlled release implantable dispensing device and method
AU2008254989B2 (en) 2007-05-14 2013-06-06 Sustained Nano Systems Llc Hypercompressed particles for controlled release of ophthalmic medications
US8071119B2 (en) 2007-05-14 2011-12-06 Sustained Nano Systems Llc Controlled release implantable dispensing device and method
KR101554250B1 (ko) * 2007-06-11 2015-09-18 알. 로치 맥도날드 뇌혈관 연축의 예방을 위한 약물 전달 시스템
JP2012524779A (ja) 2009-04-23 2012-10-18 サステインド ナノ システムズ リミテッド ライアビリティ カンパニー 制御放出分配デバイス
WO2011080141A2 (en) 2009-12-21 2011-07-07 Tibotec Pharmaceuticals Degradable removable implant for the sustained release of an active compound
JP6282231B2 (ja) * 2012-01-23 2018-02-21 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 固化するデポー形成の注入可能な薬物製剤に懸濁される持続放出された生分解性または生体侵食性微小球または微小粒子
WO2016004048A2 (en) * 2014-06-30 2016-01-07 Blend Therapeutics, Inc. Targeted conjugates and particles and formulations thereof

Also Published As

Publication number Publication date
JP2020531571A (ja) 2020-11-05
EP3651800B1 (en) 2024-04-10
US20190015336A1 (en) 2019-01-17
EP3651800A1 (en) 2020-05-20
US10406102B2 (en) 2019-09-10
CA3069159A1 (en) 2019-01-17
BR112020000506A2 (pt) 2020-07-14
IL271908A (en) 2020-02-27
EP3651800A4 (en) 2021-04-14
WO2019014280A1 (en) 2019-01-17
AU2018300080A1 (en) 2020-02-13
CN110913907A (zh) 2020-03-24
IL271908B1 (en) 2023-10-01
IL271908B2 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
RS54024B1 (en) GASTRORETENCY FORMULATION OF MEDICINES AND SYSTEMS FOR DELIVERY AND METHODS OF THEIR PREPARATION USING FUNCTIONALIZED CALCIUM CARBONATE
MX342853B (es) Tratamiento anti-envejecimiento de la piel.
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
IL257057A (en) Biologically active peptides derived from soy for use in preparations and methods for wound healing, tissue engineering and regenerative medicine
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
CY1121587T1 (el) Καψα χορηγησης
MY160922A (en) Polyethylene glycol conjugated blood coagulation factor vii
EP3513789A3 (en) Prophylactic and therapeutic agents for fgfr3 diseases
PH12018500254A1 (en) Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
SG10201902407PA (en) Injectable microparticles for hyper-localized release of therapeutic agents
MX2016014699A (es) (s)-pirlindol o sus sales farmaceuticamente aceptables para uso en medicina.
MY191219A (en) Therapeutic agent for fibrosis
MX2020000376A (es) Formulaciones farmaceuticas hipercomprimidas.
MX2019005309A (es) Anticuerpos anti-bag3 en combinacion con inhibidores del punto de control inmunitario para uso terapeutico.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2022005388A (es) Compuestos de pirrolidina y piperidina.
EA201991265A1 (ru) Лекарственные формы с отсроченным высвобождением, содержащие диметилфумарат
BR112018010497A8 (pt) combinação sinérgica de ácido pirrolidona-carboxílico e/ou seus sais e de ácido hialurônico e/ou seus sais para utilização no tratamento e/ou prevenção de secura e irritação da mucosa e suas formulações farmaceuticas relacionadas
PL3525769T3 (pl) Tabletka ulegająca rozpadowi w jamie ustnej zawierająca burlulipazę i wytworzona z niej kompozycja farmaceutyczna
EP4209500A4 (en) PEPTIDE, COSMETIC COMPOSITION AND PHARMACEUTICAL COMPOSITION COMPRISING IT
MX2022007305A (es) Mejoras en la administracion sin aguja.
IL277632A (en) CDNF fragments from the carboxyl end, pharmaceutical compositions containing them and their uses